Papers of particular interest, published within the annual period of review, have been highlighted as:
Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 517–518).
1. Vignes A. Epicanthus hereditaire. Rev Gen Ophtalmol (Paris) 1889; 8:438–439.
2. Usher CH. A pedigree of epicanthus and ptosis
. Ann Eugen 1925; 1:128–138.
3. Amati P, Chomel JC, Nivelon-Chevalier A, et al. A gene
-epicanthus inversus syndrome maps to chromosome 3q23. Hum Genet 1995; 96:213–215.
4. Small KW, Stalvey M, Fisher L, et al. Blepharophimosis syndrome is linked to chromosome 3q. Hum Mol Genet 1995; 4:443–448.
5. Crisponi L, Deiana M, Loi A, et al. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis
/epicanthus inversus syndrome. Nat Genet 2001; 27:159–166.
6. Carlsson P, Mahlapuu M. Forkhead transcription factors: key players in development and metabolism. Dev Biol 2002; 250:1–23.
7. Kohn R, Romano PE. Blepharoptosis, blepharophimosis, epicanthus inversus, and telecanthus: a syndrome with no name. Am J Ophthalmol 1971; 72:625–632.
8. Oley C, Baraitser M. Blepharophimosis, ptosis
, epicanthus inversus syndrome (BPES syndrome). J Med Genet 1988; 25:47–51.
9. Zlotogora J, Sagi M, Cohen T. The blepharophimosis, ptosis
, and epicanthus inversus syndrome: delineation of two types. Am J Hum Genet 1983; 35:1020–1027.
10. De Baere E, Dixon MJ, Small KW, et al. Spectrum of FOXL2 gene
mutations in blepharophimosis-ptosis
-epicanthus inversus (BPES) families demonstrates a genotype–phenotype correlation. Hum Mol Genet 2001; 10:1591–1600.
11. De Baere E, Beysen D, Oley C, et al. FOXL2 and BPES: mutational hotspots, phenotypic variability, and revision of the genotype-phenotype correlation. Am J Hum Genet 2003; 72:478–487.
12. Beysen D, Vandesompele J, Messiaen L, et al. The human FOXL2 mutation database. Hum Mutat 2004; 24:189–193.
13. Beaconsfield M, Walker JW, Collin JR. Visual development in the blepharophimosis syndrome. Br J Ophthalmol 1991; 75:746–748.
14. Mustarde JC. The treatment of ptosis
and epicanthal folds. Br J Plast Surg 1959; 12:252–258.
15. Anderson RL, Nowinski TS. The five-flap technique for blepharophimosis. Arch Ophthalmol 1989; 107:448–452.
16▪. Sa HS, Lee JH, Woo KI, Kim YD. A new method of medial epicanthoplasty for patients with blepharophimosis-ptosis
-epicanthus inversus syndrome. Ophthalmology 2012; 119:2402–2407.
The authors describe the results of a skin redraping method for medial canthoplasty in 16 patients with BPES.
17. Beckingsale PS, Sullivan TJ, Wong VA, Oley C. Blepharophimosis: a recommendation for early surgery in patients with severe ptosis
. Clin Experiment Ophthalmol 2003; 31:138–142.
18. Wu SY, Ma L, Tsai YJ, Kuo JZ. One-stage correction for blepharophimosis syndrome. Eye (Lond) 2008; 22:380–388.
19. Bhattacharjee K, Bhattacharjee H, Kuri G, et al. Single stage surgery for blepharophimosis syndrome. Indian J Ophthalmol 2012; 60:195–201.
20. Decock CE, De Baere EE, Bauters W, et al. Insights into levator muscle dysfunction in a cohort of patients with molecularly confirmed blepharophimosis-ptosis
-epicanthus inversus syndrome using high-resolution imaging, anatomic examination, and histopathologic examination. Arch Ophthalmol 2011; 129:1564–1569.
21. Decock CE, Shah AD, Delaey C, et al. Increased levator muscle function by supramaximal resection in patients with blepharophimosis-ptosis
-epicanthus inversus syndrome. Arch Ophthalmol 2011; 129:1018–1022.
22. Decock CE, Claerhout I, Leroy BP, et al. Correction of the lower eyelid
malpositioning in the blepharophimosis-ptosis
-epicanthus inversus syndrome. Ophthal Plast Reconstr Surg 2011; 27:368–370.
23. Engle EC. The molecular basis of the congenital fibrosis syndromes. Strabismus 2002; 10:125–128.
24. Harley RD, Rodrigues MM, Crawford JS. Congenital fibrosis of the extraocular muscles. J Pediatr Ophthalmol Strabismus 1978; 15:346–358.
25. Hiatt RL, Halle AA. General fibrosis syndrome. Ann Ophthalmol 1983; 15:1103–1109.
26. Engle EC, Goumnerov BC, McKeown CA, et al. Oculomotor nerve and muscle abnormalities in congenital fibrosis of the extraocular muscles. Ann Neurol 1997; 41:314–325.
27. Yamada K, Andrews C, Chan WM, et al. Heterozygous mutations of the kinesin KIF21A in congenital fibrosis of the extraocular muscles type 1 (CFEOM1). Nat Genet 2003; 35:318–321.
28. Marszalek JR, Weiner JA, Farlow SJ, et al. Novel dendritic kinesin sorting identified by different process targeting of two related kinesins: KIF21A and KIF21B. J Cell Biol 1999; 145:469–479.
29. Nakano M, Yamada K, Fain J, et al. Homozygous mutations in ARIX(PHOX2A) result in congenital fibrosis of the extraocular muscles type 2. Nat Genet 2001; 29:315–320.
30. Pattyn A, Morin X, Cremer H, et al. Expression and interactions of the two closely related homeobox genes Phox2a and Phox2b during neurogenesis. Development 1997; 124:4065–4075.
31. Yamada K, Chan WM, Andrews C, et al. Identification of KIF21A mutations as a rare cause of congenital fibrosis of the extraocular muscles type 3 (CFEOM3). Invest Ophthalmol Vis Sci 2004; 45:2218–2223.
32. Tischfield MA, Baris HN, Wu C, et al. Human TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance. Cell 2010; 140:74–87.
33. Gutowski NJ, Bosley TM, Engle EC. 110th ENMC International Workshop: the congenital cranial dysinnervation disorders (CCDDs). Naarden, The Netherlands, 25–27 October 2002. Neuromuscul Disord 2003; 13:573–578.
34. Oystreck DT, Engle EC, Bosley TM. Recent progress in understanding congenital cranial dysinnervation disorders. J Neuroophthalmol 2011; 31:69–77.
35. Assaf AA. Congenital innervation dysgenesis syndrome (CID)/congenital cranial dysinnervation disorders (CCDDs). Eye (Lond) 2011; 25:1251–1261.
36. Traboulsi E, Jaafar M, Kattan H, Parks M. Congenital fibrosis of the extraocular muscles: report of 24 cases illustrating the clinical spectrum and surgical management. Am Orthop J 1993; 43:45–53.
37. Ferrer J. Congenital fibrosis of the extraocular muscles. Ophthalmology 1996; 103:1517–1519.
38. Yazdani A, Traboulsi EI. Classification and surgical management of patients with familial and sporadic forms of congenital fibrosis of the extraocular muscles. Ophthalmology 2004; 111:1035–1042.
39. Falls HF, Kertesz ED. A new syndrome combining pterygium colli with developmental anomalies of the eyelids and lymphatics of the lower extremities. Trans Am Ophthalmol Soc 1965; 62:248–275.
40. Robinow M, Johnson GF, Verhagen AD. Distichiasis-lymphedema. A hereditary syndrome of multiple congenital defects. Am J Dis Child 1970; 119:343–347.
41. Temple IK, Collin JR. Distichiasis-lymphoedema syndrome: a family report. Clin Dysmorphol 1994; 3:139–142.
42. Mangion J, Rahman N, Mansour S, et al. A gene
for lymphedema-distichiasis maps to 16q24.3. Am J Hum Genet 1999; 65:427–432.
43. Fang J, Dagenais SL, Erickson RP, et al. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. Am J Hum Genet 2000; 67:1382–1388.
44. Bell R, Brice G, Child AH, et al. Analysis of lymphoedema-distichiasis families for FOXC2 mutations reveals small insertions and deletions throughout the gene
. Hum Genet 2001; 108:546–551.
45. Erickson RP, Dagenais SL, Caulder MS, et al. Clinical heterogeneity in lymphoedema-distichiasis with FOXC2 truncating mutations. J Med Genet 2001; 38:761–766.
46. Finegold DN, Kimak MA, Lawrence EC, et al. Truncating mutations in FOXC2 cause multiple lymphedema syndromes. Hum Mol Genet 2001; 10:1185–1189.
47. Mellor RH, Brice G, Stanton AW, et al. Mutations in FOXC2 are strongly associated with primary valve failure in veins of the lower limb. Circulation 2007; 115:1912–1920.
48. Miura N, Wanaka A, Tohyama M, Tanaka K. MFH-1, a new member of the fork head domain family, is expressed in developing mesenchyme. FEBS Lett 1993; 326:171–176.
49. Dagenais SL, Hartsough RL, Erickson RP, et al. Foxc2 is expressed in developing lymphatic vessels and other tissues associated with lymphedema-distichiasis syndrome. Gene
Expr Patterns 2004; 4:611–619.
50. Brice G, Mansour S, Bell R, et al. Analysis of the phenotypic abnormalities in lymphoedema-distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 16q24. J Med Genet 2002; 39:478–483.
51. Traboulsi EI, Al-Khayer K, Matsumoto M, et al. Lymphedema-distichiasis syndrome and FOXC2 gene
mutation. Am J Ophthalmol 2002; 134:592–596.
52. Kumar S, Carver C, McCall S, et al. A family with lymphoedema-distichiasis where identical twins have a discordant phenotype. Clin Genet 2007; 71:285–287.
53. Scheie HG, Albert DM. Distichiasis and trichiasis: origin and management. Am J Ophthalmol 1966; 61:718–720.
54. White JH. Correction of distichiasis by tarsal resection and mucous membrane grafting. Am J Ophthalmol 1975; 80:507–508.
55. Dortzbach RK, Butera RT. Excision of distichiasis eyelashes through a tarsoconjunctival trapdoor. Arch Ophthalmol 1978; 96:111–112.
56. Anderson RL, Harvey JT. Lid splitting and posterior lamella cryosurgery for congenital and acquired distichiasis. Arch Ophthalmol 1981; 99:631–634.
57. Frueh BR. Treatment of distichiasis with cryotherapy. Ophthalmic Surg 1981; 12:100–103.
58. Vaughn GL, Dortzbach RK, Sires BS, Lemke BN. Eyelid
splitting with excision or microhyfrecation for distichiasis. Arch Ophthalmol 1997; 115:282–284.
59. McCracken MS, Kikkawa DO, Vasani SN. Treatment of trichiasis and distichiasis by eyelash trephination. Ophthal Plast Reconstr Surg 2006; 22:349–351.
60. Lu-Emerson C, Plotkin SR. The Neurofibromatoses. Part 1: NF1. Rev Neurol Dis 2009; 6:E47–E53.
61. Cichowski K, Jacks T. NF1 tumor suppressor gene
function: narrowing the GAP. Cell 2001; 104:593–604.
62. Mulvihill JJ, Parry DM, Sherman JL, et al. NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med 1990; 113:39–52.
63▪▪. Avery RA, Dombi E, Hutcheson KA, et al. Visual outcomes in children with neurofibromatosis type 1 and orbitotemporal plexiform neurofibromas. Am J Ophthalmol 2013; 155:1089–1094.
The authors describe the visual outcomes and volumetric MRIs in 21 patients with NF1 with orbitotemporal plexiform neurofibromas. 62% of patients were found to be amblyopic secondary to their orbitotemporal plexiform neurofibroma.
64. Lee V, Ragge NK, Collin JR. Orbitotemporal neurofibromatosis. Clinical features and surgical management. Ophthalmology 2004; 111:382–388.
65. Altan-Yaycioglu R, Hintschich C. Clinical features and surgical management of orbitotemporal neurofibromatosis: a retrospective interventional case series. Orbit 2010; 29:232–238.
66. Coban-Karatas M, Altan-Yaycioglu R, Bal N, Akova YA. Management of facial disfigurement in orbitotemporal neurofibromatosis. Ophthal Plast Reconstr Surg 2010; 26:124–126.
67▪. Chaudhry IA, Morales J, Shamsi FA, et al. Orbitofacial neurofibromatosis: clinical characteristics and treatment outcome. Eye (Lond) 2012; 26:583–592.
The authors describe the clinical course and surgical outcomes of 60 patients with orbitofacial neurofibromatosis. Eleven of the patients underwent enucleation or exenteration.
68. Madill KE, Brammar R, Leatherbarrow B. A novel approach to the management of severe facial disfigurement in neurofibromatosis type 1. Ophthal Plast Reconstr Surg 2007; 23:227–228.
69. Morel E, Eymard B, Vernet-der Garabedian B, et al. Neonatal myasthenia gravis: a new clinical and immunologic appraisal on 30 cases. Neurology 1988; 38:138–142.
70. Rodriguez M, Gomez MR, Howard FM Jr, Taylor WF. Myasthenia gravis in children: long-term follow-up. Ann Neurol 1983; 13:504–510.
71. Anlar B, Ozdirim E, Renda Y, et al. Myasthenia gravis in childhood. Acta Paediatr 1996; 85:838–842.
72. Mullaney P, Vajsar J, Smith R, Buncic JR. The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children. Ophthalmology 2000; 107:504–510.
73. Engel AG. Congenital myasthenic syndromes. J Child Neurol 1988; 3:233–246.
74▪. Engel AG. Current status of the congenital myasthenic syndromes. Neuromuscul Disord 2012; 22:99–111.
Excellent review of the molecular basis of the CMS.
75. Taylor EW. Progressive vagus-glossopharyngeal paralysis with ptosis
: a contribution to the group of family diseases. J Nerv Ment Dis 1915; 42:129–139.
76. Victor M, Hayes R, Adams RD. Oculopharyngeal muscular dystrophy. A familial disease of late life characterized by dysphagia and progressive ptosis
of the eyelids. N Engl J Med 1962; 267:1267–1272.
77. Hayes R, London W, Seidman J, Embreel. Oculopharyngeal muscular dystrophy. N Engl J Med 1963; 268:163.
78. Barbeau A. Kuhn E. The syndrome of hereditary late onset ptosis
and dysphagia in French Canada. Progressive muskeldystrophie, myotonie, myasthenie; symposium 30 November bis 4 Dezember 1965 anlässlich der 125 wiederkehr des geburtstages von Wilhelm Erb. Berlin:Springer-Verlag; 1966; pp. 102–109.
79. Johnson CC, Kuwabara T. Oculopharyngeal muscular dystrophy. Am J Ophthalmol 1974; 77:872–879.
80. Brais B, Xie YG, Sanson M, et al. The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac alpha and beta myosin heavy chain genes on chromosome 14q11.2-q13. Hum Mol Genet 1995; 4:429–434.
81. Brais B, Bouchard JP, Xie YG, et al. Short GCG expansions in the PABP2 gene
cause oculopharyngeal muscular dystrophy. Nat Genet 1998; 18:164–167.
82. Blumen SC, Nisipeanu P, Sadeh M, et al. Clinical features of oculopharyngeal muscular dystrophy among Bukhara Jews. Neuromuscul Disord 1993; 3:575–577.
83. Becher MW, Morrison L, Davis LE, et al. Oculopharyngeal muscular dystrophy in Hispanic New Mexicans. JAMA 2001; 286:2437–2440.
84▪. Agarwal PK, Mansfield DC, Mechan D, et al. Delayed diagnosis of oculopharyngeal muscular dystrophy in Scotland. Br J Ophthalmol 2012; 96:281–283.
The authors review the medical records of 17 patients with OPMD and conclude that every patient could have been diagnosed earlier had physicians been knowledgeable of the disease.
85. Robinson DO, Wills AJ, Hammans SR, et al. Oculopharyngeal muscular dystrophy: a point mutation which mimics the effect of the PABPN1 gene
triplet repeat expansion mutation. J Med Genet 2006; 43:e23.
86. Robinson DO, Hilton-Jones D, Mansfield D, et al. Two cases of oculopharyngeal muscular dystrophy (OPMD) with the rare PABPN1 c.35G>C; p.Gly12Ala point mutation. Neuromuscul Disord 2011; 21:809–811.
87. Gautier D, Penisson-Besnier I, Rivaud-Pechoux S, et al. Ocular motor deficits in oculopharyngeal muscular dystrophy. Eur J Neurol 2012; 19:e38.
88. Allen RC, Jaramillo J, Black R, et al. Clinical characterization and blepharoptosis surgery outcomes in Hispanic New Mexicans with oculopharyngeal muscular dystrophy. Ophthal Plast Reconstr Surg 2009; 25:103–108.
89▪. Allen RC, Zimmerman MB, Watterberg EA, et al. Primary bilateral silicone frontalis suspension for good levator function ptosis
in oculopharyngeal muscular dystrophy. Br J Ophthalmol 2012; 96:841–845.
The authors report the surgical outcomes of 31 patients with OPMD with good levator function who underwent a primary frontalis suspension with a silicone sling and conclude that this treatment is well tolerated and effective.
90. Wallace DC. Mitochondrial diseases in man and mouse. Science 1999; 283:1482–1488.
91. Biousse V, Newman NJ. Neuro-ophthalmology of mitochondrial diseases. Curr Opin Neurol 2003; 16:35–43.
92. Almousa R, Charlton A, Rajesh ST, et al. Optimizing muscle biopsy for the diagnosis of mitochondrial myopathy. Ophthal Plast Reconstr Surg 2009; 25:366–370.
93▪. Roefs AM, Waters PJ, Moore GR, Dolman PJ. Orbicularis oculi muscle biopsies for mitochondrial DNA analysis in suspected mitochondrial myopathy. Br J Ophthalmol 2012; 96:1296–1299.
The authors report three patients in which the orbicularis muscle was biopsied during ptosis surgery. Specimens were analyzed using molecular and histological techniques. Both techniques were successful in diagnosing mitochondrial myopathy.
94. Anderson S, Bankier AT, Barrell BG, et al. Sequence and organization of the human mitochondrial genome. Nature 1981; 290:457–465.
95. Schmiedel J, Jackson S, Schäfer J, Reichmann H. Mitochondrial cytopathies. J Neurol 2003; 250:267–277.
96. Hirano M, Vu TH. Defects of intergenomic communication: where do we stand? Brain Pathol 2000; 10:451–461.
97. Servidei S. Mitochondrial encephalomyopathies: gene
mutation. Neuromuscul Disord 2001; 11:508–513.
98. Hirano M, DiMauro S. ANT1, Twinkle, POLG, and TP: new genes open our eyes to ophthalmoplegia. Neurology 2001; 57:2163–2165.
99. Kaukonen J, Juselius JK, Tiranti V, et al. Role of adenine nucleotide translocator 1 in mtDNA maintenance. Science 2000; 289:782–785.
100. Spelbrink JN, Li FY, Tiranti V, et al. Human mitochondrial DNA deletions associated with mutations in the gene
encoding Twinkle, a phage T7 gene
4-like protein localized in mitochondria. Nat Genet 2001; 28:223–231.
101. Van Goethem G, Dermaut B, Lofgren A, et al. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet 2001; 28:211–212.
102. Nishino I, Spinazzola A, Hirano M. Thymidine phosphorylase gene
mutations in MNGIE, a human mitochondrial disorder. Science 1999; 283:689–692.
103. Bohlega S, Tanji K, Santorelli FM, et al. Multiple mitochondrial DNA deletions associated with autosomal recessive ophthalmoplegia and severe cardiomyopathy. Neurology 1996; 46:1329–1334.
104. Older JJ, Dunne PB. Silicone slings for the correction of ptosis
associated with progressive external ophthalmoplegia. Ophthalmic Surg 1984; 15:379–381.
105. Shorr N, Christenbury JD, Goldberg RA. Management of ptosis
in chronic progressive external ophthalmoplegia. Ophthal Plast Reconstr Surg 1987; 3:141–145.
106. Wong VA, Beckingsale PS, Oley CA, Sullivan TJ. Management of myogenic ptosis
. Ophthalmology 2002; 109:1023–1031.
107. Ahn J, Kim NJ, Choung HK, et al. Frontalis sling operation using silicone rod for the correction of ptosis
in chronic progressive external ophthalmoplegia. Br J Ophthalmol 2008; 92:1685–1688.
108. Attie de Castro F, Cruz AA, Sobreira CF. Brow motility in mitochondrial myopathy. Ophthal Plast Reconstr Surg 2010; 26:416–419.
109▪. Pfeffer G, Mezei MM. Cardiac screening investigations in adult-onset progressive external ophthalmoplegia patients. Muscle Nerve 2012; 46:593–596.
The authors recommend a cardiologist evaluation every 3–5 years for patients with late-onset CPEO.
110. Brook JD, McCurrach ME, Harley HG, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3’ end of a transcript encoding a protein kinase family member. Cell 1992; 68:799–808.
111. Buxton J, Shelbourne P, Davies J, et al. Detection of an unstable fragment of DNA specific to individuals with myotonic dystrophy. Nature 1992; 355:547–548.
112. Fu YH, Pizzuti A, Fenwick RG Jr, et al. An unstable triplet repeat in a gene
related to myotonic muscular dystrophy. Science 1992; 255:1256–1258.
113. Musova Z, Mazanec R, Krepelova A, et al. Highly unstable sequence interruptions of the CTG repeat in the myotonic dystrophy gene
. Am J Med Genet A 2009; 149A:1365–1374.
114. Sicot G, Gourdon G, Gomes-Pereira M. Myotonic dystrophy, when simple repeats reveal complex pathogenic entities: new findings and future challenges. Hum Mol Genet 2011; 20:R116–R123.
115. Harley HG, Rundle SA, MacMillan JC, et al. Size of the unstable CTG repeat sequence in relation to phenotype and parental transmission in myotonic dystrophy. Am J Hum Genet 1993; 52:1164–1174.
116. Martorell L, Martinez JM, Carey N, et al. Comparison of CTG repeat length expansion and clinical progression of myotonic dystrophy over a five year period. J Med Genet 1995; 32:593–596.
117. Tsilfidis C, MacKenzie AE, Mettler G, et al. Correlation between CTG trinucleotide repeat length and frequency of severe congenital myotonic dystrophy. Nat Genet 1992; 1:192–195.
118▪. Call CB, Wise RJ, Hansen MR, et al. In vivo examination of meibomian gland morphology in patients with facial nerve palsy using infrared meibography. Ophthal Plast Reconstr Surg 2012; 28:396–400.
Patients with a unilateral facial nerve palsy were analyzed with infrared meibography. The side with the facial nerve palsy was found to have significantly worse meibomian gland morphology compared to the unaffected control side.
119▪▪. Shah CT, Blount AL, Nguyen EV, Hassan AS. Cranial nerve seven palsy and its influence on meibomian gland function. Ophthal Plast Reconstr Surg 2012; 28:166–168.
Patients with unilateral facial nerve palsy were found to have a significant correlation with meibomian gland dysfunction on the side of the palsy.
120. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene
encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993; 363:515–521.
121. Asthagiri AR, Parry DM, Butman JA, et al. Neurofibromatosis type 2. Lancet 2009; 373:1974–1986.
122. Baser ME, Friedman JM, Aeschliman D, et al. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 2002; 71:715–723.
123. Gailani MR, Bale SJ, Leffell DJ, et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene
on chromosome 9. Cell 1992; 69:111–117.
124. Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996; 85:841–851.
125. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene
for the basal cell nevus syndrome. Science 1996; 272:1668–1671.
126. Wicking C, Shanley S, Smyth I, et al. Most germ-line mutations in the nevoid basal cell carcinoma syndrome lead to a premature termination of the PATCHED protein, and no genotype-phenotype correlations are evident. Am J Hum Genet 1997; 60:21–26.
127. Kimonis VE, Goldstein AM, Pastakia B, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet 1997; 69:299–308.
128. Taylor SF, Cook AE, Leatherbarrow B. Review of patients with basal cell nevus syndrome. Ophthal Plast Reconstr Surg 2006; 22:259–265.
129. Honavar SG, Shields JA, Shields CL, et al. Basal cell carcinoma of the eyelid
associated with Gorlin-Goltz syndrome. Ophthalmology 2001; 108:1115–1123.
130▪. Yin VT, Pfeiffer ML, Esmaeli B. Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma. Ophthal Plast Reconstr Surg 2013; 29:87–92.
The authors review targeted therapy for orbital and periocular BCC and cutaneous squamous cell carcinoma. A patient with BCNS is presented that has been successfully treated with vismodegib.
131▪▪. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012; 366:2180–2188.
Forty-one patients with BCNS are described that were treated with vismodegib. Vismodegib was found to reduce tumor burden and block the development of new BCCs in these patients. Half of the patients discontinued the therapy due to adverse events.
132. Oji V, Tadini G, Akiyama M, et al. Revised nomenclature and classification of inherited
ichthyoses: results of the First Ichthyosis Consensus Conference in Soreze 2009. J Am Acad Dermatol 2010; 63:607–641.
133. DiGiovanna JJ, Kraemer KH. Shining a light on xeroderma pigmentosum. J Invest Dermatol 2012; 132:785–796.